Ampio Pharma: Rises on approval to test experimental drug in COVID-19

Ampio Pharmaceuticals

19/06/2020 14:01

** Shares of the drug developer  AMPE.A  climb ~23% to 70
cents premarket
    ** Wins U.S. FDA approval to test its experimental
treatment, Ampion, in patients with COVID-19  urn:newsml:reuters.com:*:nL4N2DW2S1
    ** To test if Ampion effective in interrupting inflammatory
process in lungs associated with COVID-19
    ** An injectable, Ampion targets severe osteoarthritis of
the knee and is in late-stage trial
    ** AMPE down ~2% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))